This website uses cookies
Read our Privacy policy and Terms of use for more information.
CV
+4

Sep 15, 2026
•
10 min read
Blinded trials show most muscle symptoms blamed on statins are not caused by the statin. A real minority are. SAMSON, StatinWISE, GAUSS-3, and 123,940 pooled patients measured the difference.

CV
+4

Sep 12, 2026
•
10 min read
REACT imaged 16,808 adults aged 18 to 70. More than half had atherosclerotic plaque, and a low ten-year risk estimate did not establish that arteries were plaque-free. Whether finding plaque earlier changes outcomes is still being tested.

Lp(a)
+4

Sep 5, 2026
•
8 min read
Pelacarsen lowered Lp(a) in 8,323 patients with established cardiovascular disease. It did not prevent events. What Lp(a)HORIZON teaches about the 1 in 5 — and what it can't.

CV
+4

Aug 18, 2026
•
14 min read
Remnant cholesterol costs nothing to calculate and predicts events when LDL no longer does. Its first real drug just proved it can prevent pancreatitis, and then failed to move plaque.

CV
+4

Aug 15, 2026
•
9 min read
Lp(a) is the most common inherited cardiovascular risk factor in medicine — and the first outcomes trial that could give us a drug for it has gone quiet.

Lipids
+1

Jul 18, 2026
•
2 min read
The FDA approved the first oral PCSK9 inhibitor — antibody-class LDL-C lowering from a once-daily tablet. Here is what it does, and the one thing it hasn't proven yet.

CV
+1

Jun 13, 2026
•
7 min read
A new natural-history study watched atherosclerosis grow in untreated, low-risk adults over five years — and quietly made the strongest case I’ve seen in years for treating LDL early and aggressively.

CV
+2

Jun 9, 2026
•
10 min read
Lp(a) drives heart attacks, strokes, and aortic stenosis in one in five people. Statins don’t touch it. Diet doesn’t move it. After six decades of therapeutic silence, 2026 is the year the verdict finally arrives — and a single gene edit may make the problem history.

CV
+3

Apr 15, 2026
•
16 min read
Muscle damage. Memory loss. Cancer. Diabetes. Four fears, one physician, and what the evidence actually shows.

CV
+3

Apr 11, 2026
•
12 min read
The receptor story that explains 40 years of cardiovascular outcomes data — and why the pleiotropic hypothesis was never the whole story.

GLP1
+2

Apr 8, 2026
•
14 min read
Six interventions. One thesis about time. What I take every morning and why the evidence earned each one a place in the rotation.

Michael Albert, MD. Board-certified obesity medicine physician. Chief Medical Officer, Vineyard.
Get the evidence in your inbox
Free, twice a week. Every number sourced to the trial. Unsubscribe anytime.
© 2026 Michael Albert MD LLC · Not medical advice. Dr. Albert is Chief Medical Officer of Vineyard.